Share This Page
Litigation Details for Par Pharmaceutical, Inc. v. Takeda Pharmaceutical Co., Ltd. (N.D. Cal. 2013)
✉ Email this page to a colleague
Par Pharmaceutical, Inc. v. Takeda Pharmaceutical Co., Ltd. (N.D. Cal. 2013)
| Docket | 3:13-cv-03151 | Date Filed | 2013-07-09 |
| Court | District Court, N.D. California | Date Terminated | 2013-08-08 |
| Cause | 28:2201 Declaratory Judgement | Assigned To | Elizabeth D. Laporte |
| Jury Demand | None | Referred To | |
| Patents | 7,790,755; 8,461,187 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Par Pharmaceutical, Inc. v. Takeda Pharmaceutical Co., Ltd.
Details for Par Pharmaceutical, Inc. v. Takeda Pharmaceutical Co., Ltd. (N.D. Cal. 2013)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2013-07-09 | External link to document | |||
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
Par Pharmaceutical, Inc. v. Takeda Pharmaceutical Co., Ltd. (3:13-cv-03151): Litigation Summary, Claims at Stake, and Infringement/Exclusivity Impact
Executive summary: The case captioned Par Pharmaceutical, Inc. v. Takeda Pharmaceutical Co., Ltd. under case number 3:13-cv-03151 is a federal patent dispute tied to Takeda’s brand product portfolio and Par’s generic development/launch position. In this docket format, the litigation analysis hinges on three decision points: (1) which patents Par asserted were invalid or not infringed (often via Paragraph IV in Hatch-Waxman contexts), (2) which asserted claims Takeda carried forward into claim construction and dispositive motion practice, and (3) the settlement and/or injunction posture that translated the patent estate into launch timing.
No actionable litigation specifics (asserted patent list, parties’ claims, procedural history, claim construction outcomes, settlement terms, or FDA/Orange Book triggers) are available in the provided input, so a complete and accurate litigation summary cannot be produced.
What is the litigation background for Par Pharmaceutical v. Takeda Pharmaceutical Co. (3:13-cv-03151)?
Answer (featured snippet): A complete, accurate background requires the docket’s asserted patent numbers, filing date(s), forum (district and judge), and the specific infringement theory (direct, indirect, method-of-use, formulation, or process). Those facts are not included in the request content.
What patents were asserted in 3:13-cv-03151?
A litigation summary must list:
- U.S. patent numbers asserted
- Patent owners/assignees (Takeda vs. co-owners)
- Which product (drug strength, dosage form, or label)
- Which claims were targeted (independent and dependent claim identifiers)
None of those elements are provided.
What claims did Par challenge or seek to negate?
For Hatch-Waxman-style disputes, the high-value facts are:
- Paragraph IV vs. non-Paragraph IV posture
- Invalidity arguments (anticipation/obviousness/indefiniteness/enablement)
- Non-infringement arguments (label vs. product formulation differences)
- Design-around facts that affected claim construction
Those facts are not available.
What claims and defenses drove the infringement analysis in Par v. Takeda (3:13-cv-03151)?
Answer (featured snippet): In patent disputes, the “driving issues” are claim-construction outcomes and whether the accused product reads onto the construed claim limitations. The case-specific claim set is required to summarize infringement and defenses.
How did claim construction shape infringement outcomes?
To analyze infringement strength, the report must tie:
- claim construction rulings to
- the accused Par product specifications and manufacturing steps
- any doctrine-of-equivalents posture
No claim construction record is included.
What invalidity theories were used against Takeda’s patents?
A litigation-grade analysis typically covers:
- anticipation and obviousness references
- prosecution history estoppel impacts
- written description and enablement attacks
- indefiniteness challenges
No invalidity grounds are provided.
Were there stipulations or narrowing amendments?
Litigation summaries often hinge on:
- amended pleadings
- narrowed claim sets
- agreed non-infringement positions
No such procedural facts are provided.
When does exclusivity end in Par v. Takeda (3:13-cv-03151) and what is the launch timing impact?
Answer (featured snippet): Exclusivity and launch timing outcomes depend on:
- patent expiration dates (utility and any terminal disclaimers)
- regulatory exclusivity (NCE, pediatric, 180-day exclusivity, etc.)
- any court-ordered injunction or settlement “carve-outs”
- whether patents were found invalid, unenforceable, or not infringed
The input provides none of the necessary regulatory or patent expiration particulars.
What patent expiration dates were at issue?
A proper timeline requires:
- each asserted patent’s expiration
- any adjustments (term extension)
- PTE/PTE interaction with the Orange Book listing
No patent data is provided.
Did settlement trigger “launch-at-risk” or delayed entry?
To assess commercial impact, the analysis must identify:
- settlement date
- earliest permitted launch date
- any payment-for-delay structure (if applicable)
- any ongoing litigation dismissed without prejudice vs. with prejudice
No settlement terms are provided.
What is the Orange Book status of Takeda’s product(s) implicated in 3:13-cv-03151?
Answer (featured snippet): Orange Book analysis requires the specific FDA application(s), listed patents, and expiration/exclusivity status. The request does not provide product name, NDA/ANDA number, or Orange Book identifiers.
Which Orange Book-listed patents overlapped with the asserted litigation patents?
The litigation summary should map:
- Orange Book listed patents to
- asserted court patents
- any mismatch (different patents, different claim scope, or continuation patents)
No Orange Book mapping is included.
Which FDA pathway drove the Paragraph IV posture, if any?
A credible analysis depends on whether Par filed:
- ANDA under Hatch-Waxman with Paragraph IV certification
- 505(b)(2)
- other route
No pathway details are provided.
Who were the parties’ legal positions in Par Pharmaceutical v. Takeda (3:13-cv-03151)?
Answer (featured snippet): The “legal position” is summarized by the pleadings and the postured relief:
- Par’s requested judgment on invalidity/non-infringement and attorneys’ fees
- Takeda’s requested injunction and infringement findings
- any counterclaims (e.g., declaratory judgment)
The pleadings content is not in the input.
What relief did Par seek?
Common outcomes:
- non-infringement declaration
- invalidation
- dissolution of any stay
- attorneys’ fees under 35 U.S.C. § 285
No requested relief details are provided.
What relief did Takeda seek?
Common outcomes:
- injunction under 35 U.S.C. § 283
- permanent injunction
- exclusionary order
- damages for pre-launch activity (rare, but depends on posture)
No requested relief details are provided.
What happened procedurally in 3:13-cv-03151 (motions, hearings, rulings)?
Answer (featured snippet): A litigation summary must cover procedural milestones:
- complaint and answer dates
- initial scheduling order
- Markman/claim construction timeline
- summary judgment motions
- trial/settlement dismissal timing
No docket dates or ruling identifiers are provided.
Key milestone table
| Milestone | Required docket detail | Status in provided input |
|---|---|---|
| Complaint filed | date, patents, counts | not provided |
| Claim construction (Markman) | dates and constructions | not provided |
| Dispositive motions | summary judgment/injunction motions | not provided |
| Final outcome | judgment, dismissal, settlement | not provided |
How strong is Takeda’s patent estate based on 3:13-cv-03151 litigation outcomes?
Answer (featured snippet): Litigation strength is measured by:
- how many asserted claims survived claim construction and dispositive motions
- invalidation outcomes (all vs. partial vs. none)
- enforceability findings
No outcome findings are provided.
Were asserted patents sustained or narrowed?
A credible strength assessment requires:
- infringement determination on each asserted claim
- validity determination per asserted patent
Not available in the provided input.
What generic entry risks exist for Par or other challengers following 3:13-cv-03151?
Answer (featured snippet): Entry risk hinges on:
- whether Takeda won with enforceable patents still in force
- whether the court invalidated core claims
- whether any surviving claims create residual launch barriers
No judgment or post-judgment posture is provided.
How does Par’s litigation position compare with other challengers to Takeda products?
Answer (featured snippet): Comparative analysis requires:
- other defendants’ cases and outcomes
- whether the same patents are asserted in the same posture
- whether settlements share similar launch terms
No comparative case list is provided.
Key Takeaways
- A litigation summary for Par Pharmaceutical, Inc. v. Takeda Pharmaceutical Co., Ltd. (3:13-cv-03151) requires the docket-specific record: asserted patents, claim sets, procedural history, and outcome/settlement terms.
- Those case-specific facts are not present in the provided input, so an accurate litigation summary and analysis cannot be completed.
FAQs
- Which patents were asserted in Par Pharmaceutical v. Takeda (3:13-cv-03151) and what claims were targeted?
- Did the court conduct Markman claim construction in 3:13-cv-03151, and what were the construed limitations?
- What was the outcome of dispositive motions (summary judgment) in 3:13-cv-03151?
- Did 3:13-cv-03151 end in settlement, and what launch timing terms resulted?
- Which FDA application(s) and Orange Book listed patents correspond to the litigation patents asserted in 3:13-cv-03151?
References (APA)
- None provided in the request content.
More… ↓
